A comprehensive research on identifying factors to predict transition to psychosis in participants at At-Risk Mental State by using Rorschach profiles and stress-related biomarkers in saliva.

A comprehensive research on identifying factors to predict transition to psychosis in participants at At-Risk Mental State by using Rorschach profiles and stress-related biomarkers in saliva. - Predictive factors for transition to psychosis in ARMS subjects

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038573

Enrollment

168

Registered

2019-11-15

Start date

2019-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia, At-Risk Mental State

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Basic standards 1)Provide consent to sample bioinformation, capable and willing to follow the research process. 2)Age between 15 to 40 3)Total IQ higher than or equal to 70 UHR group 1)Meet at least one out of the three types of symptomatology as below (You should be aware that the three types of prodromal symptoms are not mutually exclusive. A patient may fulfill more than one type of symptomatology). The Criteria of Prodromal Syndromes: COPS A)Brief Intermittent Psychotic Syndromes: BIPS B)Attenuated Positive Symptom Syndrome: APSS C)Genetic Risk and Deterioration Syndrome: GRDS Health Controls 1)Healthy controls, who were age and sex matched with UHR group.

Exclusion criteria

Exclusion criteria: 1)Those who have neurologic or medical neurologic or medical conditions as below: history of head trauma with loss of consciousness, chronic pulmonary disease, kidney disease, chronic liver disease, thyroid disease, active cancer, cerebrovascular disease, epilepsy, neurological disorder, substance related disorder, or mental retardation(IQ<70), obvious history of psychosis. 2)Those who are not seeking for help. 3)Those who suffer from autoimmune disease (SLE, hyperthyroidism: Graves' disease, ulcerative colitis, Crohn's disease). 4)Regular use of steroid or NSAID. 5)The attending physician decided that the patient was inappropriate to participate in the study.

Design outcomes

Primary

Measure	Time frame
(a)Rorschach test (b)Structured Interview for Prodromal Syndromes: SIPS (c)The Scale of Prodromal Symptoms: SOPS (d)Cortisol in saliva 2ml: alpha-Amylase, CRP (C-Reactive Protein), IL-6, IL-1-beta, in saliva.	—

Secondary

Measure	Time frame
(a)the Scale to Assess Unawareness of Mental Disorder Japanese Version: SUMD-J (b)Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version: SWNS-J (c)Positive and Negative Syndrome Scale: PANSS (d)The Brief Assessment of Cognition in Schizophrenia: BACS (e)Beck Depression Inventory-2: BDI-2 (f)Height, weight, smoking status	—

Countries

Japan

Contacts

Public ContactNaoko Kishimoto

Nara Medical University Department of Psychiatry Psychiatric Institute

naoko@naramed-u.ac.jp+81-744-22-3051

Outcome results